Carolyn A. Bondy, MD; Louis E. Underwood, MD; David R. Clemmons, MD; Hans-Peter Guler, MD; Mark A. Bach, MD, PhD; Monica Skarulis, MD
Insulin-like growth factor I (IGF-I) has acute insulin-like metabolic effects and long-term anabolic actions. The therapeutic potential of recombinant human IGF-I treatment is being investigated in various growth hormone-resistant and insulin-resistant disorders. Recent studies have shown that IGF-I may substitute for growth hormone in promoting linear growth in children with growth hormone insensitivity. The anabolic, protein-sparing action of IGF-I is being evaluated as a potential therapy for adults with catabolic diseases. Patients with insulin-dependent diabetes mellitus have reduced endogenous IGF-I production, and studies are in progress to determine whether treatment with IGF-I in addition to insulin may improve their metabolic/anabolic status. Insulin-like growth factor I treatment may reduce glucose and triglyceride levels in adults with non–insulin-dependent diabetes mellitus and in some patients with extreme insulin resistance. Further studies are needed to evaluate the efficacy and safety of IGF-I treatment in these and other conditions and to provide a better understanding of this hormone's normal physiologic role(s) and complex relations with growth hormone and insulin.
Growth hormone and insulin both stimulate hepatic IGF-I production, and IGF-I feeds back to suppress growth hormone and insulin release. Insulin-like growth factor-binding protein-3 (BP3) and the associated acid-labile subunit (ALS) levels are positively regulated by growth hormone, whereas IGF-binding protein-1 (BP1) levels are negatively regulated by insulin.
Under normal conditions, growth hormone secreted by the pituitary gland stimulates production of IGF-I by liver and other tissues. Insulin-like growth factor I, in turn, stimulates proliferation of cartilage, statural growth, and growth of other tissues. Insulin-like growth factor I exerts feedback suppression of growth hormone at the level of the hypothalamus and pituitary gland. In the Laron syndrome, defective growth hormone receptors cause unresponsiveness to growth hormone, low IGF-I levels, poor growth, and reduced feedback suppression of growth hormone secretion. The goal for treating such patients is to bypass the need for growth hormone by administering IGF-I. In patients with deletion of the growth hormone gene, growth hormone is sometimes ineffective as a long-term treatment for delayed growth because of the development of large amounts of antibodies that bind growth hormone in the circulation and inhibit its action. In these patients, administering IGF-I should bypass the need for growth hormone.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Bondy CA, Underwood LE, Clemmons DR, Guler H, Bach MA, Skarulis M. Clinical Uses of Insulin-like Growth Factor I. Ann Intern Med. 1994;120:593–601. doi: 10.7326/0003-4819-120-7-199404010-00011
Download citation file:
Published: Ann Intern Med. 1994;120(7):593-601.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only